依奇珠单抗治疗中重度银屑病:生物制剂初治与经治患者的整合分析
本研究整合两项Ⅲ期随机对照试验的12周诱导期数据,比较依奇珠单抗(80mg每2周或每4周)与依那西普、安慰剂在中重度银屑病患者中的疗效与安全性。结果显示,每2周依奇珠单抗在生物制剂经治与初治患者中PASI 75应答率相似(91.5% vs 87.7%),而依那西普在经治患者中应答率较低(34.6% vs 50.7%)。
要点
- 依奇珠单抗80mg每2周在生物制剂经治与初治患者中疗效相似。
- 依那西普在生物制剂经治患者中应答率低于初治患者。
- 各依奇珠单抗剂量组PASI 90/100应答率均优于依那西普。
核心结论
- 依奇珠单抗80mg每2周在生物制剂经治与初治患者中均显示高效,而依那西普在经治患者中疗效较低。
研究设计与样本
- 患者接受依奇珠单抗80mg每2周(N=736)、每4周(N=733)、安慰剂(N=361)或依那西普50mg每周两次(N=740)。
主要发现
- 生物制剂经治患者497例(19.3%),初治患者2073例(80.7%)。
- 依奇珠单抗每2周组PASI 75应答率:经治91.5%,初治87.7%;每4周组:经治76.2%,初治82.2%;依那西普组:经治34.6%,初治50.7%。
- PASI 90和PASI 100应答率在各亚组中均显示依奇珠单抗优于依那西普。
关键数值与推荐
- PASI 75、PASI 90、PASI 100应答率于第12周评估。
- 缺失值按无应答处理,采用Cochran-Mantel-Haenszel检验按研究分层分析。
临床怎么用
- 对于生物制剂经治的中重度银屑病患者,依奇珠单抗80mg每2周仍可提供高应答率。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biologics are effective for the treatment of psoriasis. However, treatment outcomes may differ among biologic-naive patients and those switched from previous biological therapies. OBJECTIVES: The study's objective was to investigate efficacy and safety of ixekizumab, a high-affinity anti-interleukin-17A antibody, in patients with psoriasis with and without previous exposure to biologics. METHODS: Data were integrated from the 12-week induction phase of two etanercept-controlled Phase III trials. Patients received 80 mg ixekizumab every 2 weeks (IXE Q2W; N = 736) or every 4 weeks (IXE Q4W; N = 733) following a 160-mg starting dose, or placebo (N = 361). Etanercept (50 mg twice weekly; N = 740) was administered as active control. Psoriasis Area and Severity Index (PASI) 75, PASI 90 and PASI 100 response rates at week 12 were evaluated in patients with or without previous exposure to biologics. Treatment effects were analysed with the Cochran-Mantel-Haenszel test stratified by study; missing values were imputed as non-response. RESULTS: Overall, 497 (19.3%) patients had prior exposure to biologics and 2073 (80.7%) were naive to biologic therapy. PASI 75 was achieved by 91.5% of biologic-experienced patients and 87.7% of biologic-naive patients for IXE Q2W, 76.2% and 82.2% for IXE Q4W, respectively, and 34.6% and 50.7%, respectively, for etanercept. Higher response rates favouring each ixekizumab dose over etanercept within subgroups were also seen regarding PASI 90 and PASI 100. CONCLUSIONS: Contrary to etanercept, the efficacy of ixekizumab was similarly high in patients with and without previous exposure to biologics when administered 80 mg every 2 weeks.
引用
- Gottlieb AB, Lacour JP, Korman N, et al. Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies. J Eur Acad Dermatol Venereol. 2016. PMID: 27696577. doi:10.1111/jdv.13990
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。